相关实验视频

Updated: Jun 7, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

具有潜在抗癌活性的工程性多孔β-cyclopodextrin载荷拉洛西芬框架:物理化学特征,药物释放和细胞毒性研究

Jana K Alwattar^1,2, Mohammed M Mehanna^3,4

¹Department of Pharmaceutical Sciences, School of Pharmacy, Lebanese International University, Beirut, Lebanon.

International journal of nanomedicine

|November 14, 2024

概括

这项研究开发了装有拉洛西芬的纳米海绵,以改善乳腺癌治疗. 纳米海绵增强了药物溶解性和抗癌活性,显示出作为一种新型药物递送系统的前景.

科学领域:

制药科学制药科学
材料科学材料科学材料科学
在瘤学瘤学.

背景情况:

乳腺癌是导致死亡的主要原因,特别是在女性中.
拉洛西芬是一种选择性雌激素受体调节剂,用于乳腺癌治疗,但具有较差的水溶性.
基于β-cyclodextrin的纳米海绵提供了一种新的方法来增强难溶性药物的可溶性和溶解性.

研究的目的:

通过使用纳米海绵,研究提高拉洛西芬的可溶性和溶解率.
为了评估raloxifene装载的纳米海绵对乳腺癌细胞系的细胞毒性活动.

主要方法:

制造和优化与二碳酸盐交叉连接的循环德素纳米海绵.
使用FTIR,PXRD,TEM和SEM进行纳米海绵的表征.
在MCF-7细胞上的溶解性,溶解性和细胞毒性的体外评估.

主要成果:

装有拉洛西芬的纳米海绵显示颗粒大小为440±8.5nm和负泽塔电位.
显著增强了拉洛西芬的体外溶解行为.
与自由拉洛芬相比,加载纳米海绵对MCF-7细胞的细胞毒性在体外具有统计学意义.

结论:

开发的纳米海绵有效地提高了拉洛西芬的可溶性和溶解.
将拉洛西芬纳入纳米海绵增强了其抗癌活性.
装有拉洛西芬的纳米海绵是抗癌药物输送的有希望的纳米载体.

关键词:

这是一种抗癌药物.这是一种β-cyclodextrin.乳腺癌乳腺癌乳腺癌这些是纳米海绵.拉洛西芬的使用方法

更多相关视频

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...